All Posts

EverGlade Consulting (“EverGlade”), a national consulting firm, has helped a leading biotechnology company land an award from the Biomedical Advanced Research and Development Authority (BARDA) with a potential $1 billion in federal funding. This multi-year contract will allow the Company to advance the development of a full portfolio of innovative solutions to address influenza and […]

President Biden recently launched the administration’s new National Biodefense Strategy and Implementation Plan. The strategy reflects changing dynamics in Washington, especially given the lack of additional funding for COVID.  National BiodefenseStrategy and Implementation Summarized The plan calls for $88B in additional funding over 5 years and is focused on the following goals: Detect pandemics and

EverGlade Consulting (“EverGlade”), a national consulting firm, has successfully partnered with a global leader in mRNA materials used for research, diagnostics, and therapeutics, to successfully manage $39 million in federal funding. The Industrial Base Expansion (IBx) project will expand the domestic production capacity for materials that are critical to the development and manufacture of mRNA

As of August 10, the Center for Disease Control (CDC) reported that over 10,000 cases of monkeypox have been identified in the United States (US). The Biden administration officially declared monkeypox a Public Health Emergency (PHE) in the US on August 4th, following several states that declared their own state of emergency (New York, California,

With the government fiscal year ending in a few short weeks and Covid continuing to impact the country, new government funding opportunities are plentiful for organizations supporting both the pandemic response and other areas of interest in the new Senate appropriations bill which will head for a vote by September 30, 2022. One of the

EverGlade Consulting (“EverGlade”), a Washington, D.C. based consulting firm, has successfully aided Detect, Inc. (“Detect”) in securing a contract with BARDA for the advanced development of a next-generation diagnostic device which is an over-the-counter home test that identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid using a single nasal swab.